Showing results (1281-1290 of 10,440) with videos related to

Sort By:
Pageof 1,044
AIDS (London, England)|June 5, 2002
Evaluating the risk of HIV transmission through unprotected orogenital sexJorge del Romero, Beatriz Marincovich, Jesús Castilla, et al.
AIDS (London, England)|June 6, 2000
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study TeamC Katlama, B Clotet, A Plettenberg, et al.
AIDS (London, England)|June 6, 2000
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavirE H Gisolf, R P van Heeswijk, R W Hoetelmans, et al.
AIDS (London, England)|June 6, 2000
Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremiaL Ross, M Johnson, R DeMasi, et al.
AIDS (London, England)|June 6, 2000
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapyT R O'Brien, D H McDermott, J P Ioannidis, et al.
AIDS (London, England)|June 6, 2000
CD4 cell counts in adults with newly diagnosed HIV infection: results of surveillance in England and Wales, 1990-1998. CD4 Surveillance Scheme Advisory GroupS B Gupta, R L Gilbert, A R Brady, et al.
AIDS (London, England)|June 15, 2000
Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study GroupM Núñez, A Machuca, V Soriano, et al.
AIDS (London, England)|June 15, 2000
The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophilsG Florio, A Petraroli, V Patella, et al.
AIDS (London, England)|June 15, 2000
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapyG R Kaufmann, M Bloch, J J Zaunders, et al.
AIDS (London, England)|June 15, 2000
Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapyC A Sabin, T T Yee, H Devereux, et al.
Pageof 1,044